Publicaciones en colaboración con investigadores/as de Hospital Son Llàtzer (26)

2026

  1. Clinical outcomes of long-acting cabotegravir and rilpivirine in people with HIV aged 60 and older: Real-world data from the Spanish RELATIVITY cohort

    HIV Medicine, Vol. 27, Núm. 1, pp. 58-73

  2. Determinants of long-acting cabotegravir plus rilpivirine discontinuation in real-world HIV care: insights from the RELATIVITY cohort

    AIDS, Vol. Publish Ahead of Print

  3. Effectiveness and Persistence of Long-Acting Injectable Cabotegravir and Rilpivirine in Migrant Individuals Living With HIV in Spain: Substudy of the RELATIVITY Cohort

    Journal of the International AIDS Society, Vol. 29, Núm. 4

  4. Effectiveness of a Comprehensive Program Including a Novel Concentrated High-Protein, High-Calorie Oral Nutritional Supplement to Enhance Nutritional and Morphofunctional Recovery in Malnourished Patients with Cancer: The ONAVIDA Study

    Nutrients , Vol. 18, Núm. 9

  5. Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort

    AIDS (London, England), Vol. 40, Núm. 4, pp. 414-427

  6. Impact of thrombosis on disease progression, cancer and mortality in patients with essential thrombocythemia and polycythemia vera

    Blood Cancer Journal

  7. Long-acting cabotegravir and rilpivirine in people with HIV and obesity: Real-world outcomes from the RELATIVITY cohort

    HIV Medicine, Vol. 27, Núm. 5, pp. 690-709

  8. Transthyretin-related cardiac amyloidosis. A review of current treatments and future prospects

    REC: CardioClinics

  9. Trends in Hepatitis C Virus Infection Prevalence Among People With HIV in Spain Over 2 Decades (2002-2023)

    Clinical Infectious Diseases, Vol. 82, Núm. 3, pp. e511-e520

2025

  1. A prospective assessment of the efficacy and durability of long-acting cabotegravir and rilpivirine in individuals with HIV in Spain (RELATIVITY study)

    Journal of Antimicrobial Chemotherapy, Vol. 80, Núm. 12, pp. 3438-3451

  2. Assessing LDL-C Levels and Lipid-Modifying Therapies in a Real-World Cohort of Patients with Atherosclerotic Cardiovascular Disease: The REALITY Study

    Journal of Clinical Medicine, Vol. 14, Núm. 7

  3. Hereditary transthyretin amyloidosis caused by the Val142Ile variant in Spain

    Revista Espanola de Cardiologia, Vol. 78, Núm. 9, pp. 768-777

  4. Laboratory Prognostic Index (LAB-PI) in diffuse large B-cell lymphoma: a single blood analysis predicts outcomes as good as IPI, NCCN-IPI, and GELTAMO-IPI

    ESMO Open, Vol. 10, Núm. 12

  5. Left ventricular ejection fraction decline and cardiovascular events in suspected cardiomyopathy with excessive trabeculation: toward precision medicine

    Revista Espanola de Cardiologia, Vol. 78, Núm. 11, pp. 934-944

  6. Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial

    The Lancet HIV, Vol. 12, Núm. 7, pp. e473-e484

  7. Mechanical power is not associated with mortality in COVID-19 mechanically ventilated patients

    Annals of Intensive Care, Vol. 15, Núm. 1

  8. The p.Asn271Ile Variant in the TNNT2 Gene Is Associated With Low-Risk Late-Onset Hypertrophic Cardiomyopathy

    JACC: Heart Failure, Vol. 13, Núm. 12

2022

  1. Consensus on the Management of the COPD Patient in the COVID-19 Setting: COPD Forum Working Group

    Archivos de Bronconeumologia, Vol. 58, Núm. 11, pp. 776-779

  2. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57)

    Open Forum Infectious Diseases

  3. Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019

    HIV Medicine, Vol. 23, Núm. 7, pp. 705-716